Lilly gets rare downgrade as analysts question hype over GLP-1 pills and Zepbound’s cash sales
The Big Market Report Take
If middle-class Americans lose their jobs to AI, that could mean fewer cash sales of weight-loss drugs like Zepbound.
Not financial advice. The Big Market Report aggregates news for informational purposes only. Nothing on this site constitutes investment advice. Equities and other securities are subject to market risk. Always do your own research and consult a qualified financial advisor before making any investment decisions. Full disclaimer →
Never miss a story
More from this section
- Sable Offshore Stock: The Surge Offers A Great Exit Point (Downgrade)Seeking Alpha3m ago
- Contango Ore, Inc. (CTGO) Shareholder/Analyst Call Prepared Remarks TranscriptSeeking Alpha13m ago